Peripheral T-Cell Lymphoma Market Outlook 2034: US Market Surpasses USD 500 Million in 2023 with 12,600+ Cases Driving Demand for Next-Gen Treatments, analyses DelveInsight

Peripheral T-Cell Lymphoma Market

In 2023, the US led the Peripheral T-Cell Lymphoma (PTCL) therapeutics market in the 7MM, valued at USD 500 million, followed by Japan. Newly diagnosed PTCL patients are primarily treated with anthracycline-based chemotherapy regimens like CHOP, CHOEP, or other multidrug combinations. The US reported approximately 12,600 PTCL cases in 2023, with numbers expected to rise by 2034. A new treatment approach, CHP-BV (cyclophosphamide, doxorubicin, prednisone, and brentuximab vedotin), is emerging for ALCL. In Japan, therapies like HIYASTA for ATLL and PTCL, along with DARVIAS and REMITORO for relapsed/refractory cases, are expanding treatment options. The innovative CAR-T and NK cell therapies are entering PTCL research, currently in preclinical and early clinical trial stages. Additionally, novel biologics targeting immune checkpoints (PD-1/PD-L1), NK-cell engagers, anti-CD47 antibodies, and mogamulizumab (CCR4-targeting) are creating new opportunities for more disease-specific and effective PTCL treatments.

DelveInsight’s “Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Peripheral T-cell Lymphoma, historical and forecasted epidemiology as well as the Peripheral T-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Peripheral T-cell Lymphoma market report offers information on current treatment methods, new drugs, the market share of different therapies, and the present and projected size of the Peripheral T-cell Lymphoma market from 2020 to 2034. The report is divided into segments covering seven major markets. Additionally, it includes details about the current treatment practices and algorithms for Peripheral T-cell Lymphoma, factors driving the market, obstacles faced, and areas with unmet medical needs. This comprehensive report aims to identify the best opportunities and evaluate the potential of the Peripheral T-cell Lymphoma market.

Unlock key insights into the evolving Peripheral T-cell Lymphoma (PTCL) market with DelveInsight’s latest report. Discover emerging therapies, market trends, patient forecasts, and growth opportunities across the US, EU5, and Japan. Download the report now to stay ahead in the PTCL space! @ Peripheral T-cell Lymphoma Market Forecast

Key takeaways from Peripheral T-Cell Lymphoma (PTCL) Market Report:

• The Peripheral T-cell Lymphoma market size in the United States is projected to grow steadily at a healthy CAGR from 2020 to 2034.
• Leading companies developing Peripheral T-cell Lymphoma treatments include Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, among others.
• Key therapies expected to launch in the Peripheral T-cell Lymphoma market include Beleodaq (Belinostat, Acrotech Biopharma), Istodax (Romidepsin), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics), among others.
• In 2021, the total number of Peripheral T-cell Lymphoma cases across the seven major markets (7MM) was approximately 18,027 and this figure is anticipated to rise during the forecast period.
• In June 2025, Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present research findings on two of its first-in-class hematologic oncology assets—golidocitinib and DZD8586—at the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). These include long-term follow-up data on golidocitinib as a maintenance therapy in peripheral T-cell lymphoma (PTCL) after first-line systemic therapy and pooled analysis results for DZD8586 in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), both selected for oral presentations at ICML.
• In April 2025, Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global registration Phase 3 study of linperlisib versus physicians’ choice of standard of care for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). FDA’s approval of the pivotal Phase 3 protocol follows a successful Type B End-of-Phase 2 meeting, during which Yingli Pharma discussed the overall development program and regulatory path. The Phase 3 study is planned to commence during the second quarter of 2025. Linperlisib is a potent oral small molecule inhibitor of the delta isoform of PI3 kinase (PI3Kδ) developed by Yingli Pharma.
• In March 2025, Corvus Pharmaceuticals announced new data from their Phase 1/1b clinical trial of soquelitinib for T-cell lymphoma patients, which was presented at the 16th Annual T-Cell Lymphoma Forum held in San Diego.
• In February 2025, Pfizer announced that the FDA approved the supplemental Biologics License Application for ADCETRIS® (brentuximab vedotin) combined with lenalidomide and rituximab for adults with relapsed or refractory large B-cell lymphoma who are ineligible for stem cell transplant or CAR-T therapy.
• In August 2024, Viracta Therapeutics reported positive Phase 2 results from the NAVAL-1 trial targeting relapsed or refractory Epstein-Barr virus-positive Peripheral T-cell Lymphoma. The FDA provided feedback supporting a regulatory path forward, with plans for a randomized controlled trial in late 2025.
• In April 2024, Affimed GmbH shared results from a Phase 2 study combining Innate Cell Engager AFM13 with allogeneic natural killer cells for patients with recurrent or refractory Hodgkin Lymphoma and CD-30 positive Peripheral T-cell Lymphoma.
• In April 2024, Astex Pharmaceuticals announced Phase 1-2 trial outcomes evaluating the safety, pharmacokinetics, and initial activity of Tolinapant combined with oral Decitabine/Cedazuridine in relapsed/refractory Peripheral T-cell Lymphoma patients.
• In February 2024, Acrotech Biopharma revealed Phase 3 results comparing the efficacy and safety of Beleodaq-CHOP or Folotyn-COP versus CHOP alone in newly diagnosed Peripheral T-cell Lymphoma patients.

Peripheral T-cell Lymphoma Overview

Peripheral T-cell lymphoma (PTCL) is a rare and aggressive group of non-Hodgkin lymphomas that arise from mature T-cells and natural killer (NK) cells. PTCL accounts for a small percentage of all lymphomas but tends to have a poorer prognosis compared to B-cell lymphomas due to its aggressive nature and resistance to conventional therapies. It includes several subtypes, such as anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Symptoms often include swollen lymph nodes, fever, weight loss, and night sweats. Diagnosis typically involves biopsy, immunophenotyping, and imaging studies. Standard treatment usually starts with anthracycline-based combination chemotherapy regimens like CHOP or CHOEP. However, many patients experience relapse or refractory disease, prompting the development of novel therapies, including targeted agents, immunotherapies, and cellular therapies. Ongoing research and clinical trials aim to improve outcomes and provide new options for patients with this challenging disease.

Peripheral T-cell Lymphoma Market Outlook

As new targetable mutations are identified and targeted drugs developed, treatment options for Peripheral T-cell Lymphoma (PTCL) are expanding rapidly. However, given PTCL’s aggressive and diverse nature, it remains a therapeutic challenge. Standard first-line treatments mainly include anthracycline-based chemotherapy regimens such as CHOP or CHOEP, but nearly a quarter of patients develop refractory disease, and many relapse with poor overall survival. The FDA has approved several drugs, including BELEODAQ, ISTODAX, FOLOTYN, ARRANON, XALKORI, and notably ADCETRIS (Brentuximab vedotin), which reshaped the market by becoming the first approved first-line therapy for certain PTCL subtypes. Key companies like Secura Bio, HUYA Bioscience, Verastem, and others are advancing clinical candidates. The global PTCL therapeutics market was valued at approximately USD 680 million in 2020, with steady growth projected. Emerging therapies like Viracta’s Nanatinostat target EBV+ T-cell lymphomas, showing promise in ongoing clinical trials.

Stay ahead in the evolving Peripheral T-cell Lymphoma (PTCL) landscape. Explore key insights, emerging therapies, and market opportunities in DelveInsight’s comprehensive PTCL report. Download now to uncover the future of PTCL treatment and innovation! @Peripheral T-Cell Lymphoma Treatment Market

PTCL Market Drivers

• Rising Incidence of PTCL: Increasing diagnosis rates in the US, EU5, and Japan are fueling demand for effective treatments.
• Advancements in Targeted Therapies: Development of novel agents such as HDAC inhibitors, monoclonal antibodies, and CAR-T therapies is expanding treatment options.
• Unmet Clinical Needs: Limited efficacy of conventional chemotherapy creates opportunities for new drugs with better safety and efficacy profiles.
• Growing R&D Investments: Pharmaceutical companies and research institutes are actively conducting clinical trials to bring innovative therapies into the market.
• Regulatory Support and Approvals: Accelerated approval pathways and orphan drug designations encourage faster development of PTCL therapies.
• Expanding Awareness: Increased awareness among healthcare professionals and patients supports early diagnosis and treatment adoption.

PTCL Market Barriers

• Rarity of PTCL: As a rare and heterogeneous cancer, patient pool limitations restrict large-scale trials and revenue potential.
• High Treatment Costs: Novel targeted therapies and immunotherapies are expensive, limiting accessibility in some markets.
• Adverse Effects of Therapies: Severe side effects associated with chemotherapy and newer drugs can affect adoption.
• Limited Biomarkers: Lack of reliable biomarkers for predicting treatment response hampers precision medicine approaches.
• High Clinical Trial Failure Rate: Complex disease biology and heterogeneous subtypes lead to frequent late-stage trial failures.
• Competition from Existing Therapies: Generic chemotherapies and supportive treatments continue to dominate due to affordability.

Peripheral T-cell Lymphoma Epidemiology

Peripheral T-cell lymphoma (PTCL) subtypes show regional variations: PTCL-NOS is more common in the US and Europe, while ATLL and NKTCL are more prevalent in Asia. ATLL is frequent in Japan but rare elsewhere in Asia, where NKTCL represents 44% of cases (excluding Japan). ALCL, ALK-positive, is most common in North America, and enteropathy-type PTCL is most often seen in Europe. In 2023, Germany had the highest PTCL cases among the EU4 and the UK, followed by the UK, with Spain reporting the fewest. Most PTCL cases were diagnosed at advanced stages (III–IV). Additionally, around 1,150 ATLL cases in Japan in 2023 showed CD30 expression.

Peripheral T-cell Lymphoma Epidemiology Segmentation in the 7MM

• Total Peripheral T-cell Lymphoma Incident Cases
• Peripheral T-cell Lymphoma Stage-Specific Incident Cases (Stage I, Stage II, Stage III, and Stage IV)
• Peripheral T-cell Lymphoma Subtype-Specific Incident Cases (PTCL-NOS, ALCL, AITL, nasal NK/T-cell lymphoma, enteropathy-type intestinal TCL, hepatosplenic TCL, and others)

Uncover regional and subtype-specific insights into Peripheral T-cell Lymphoma across the 7MM. Stay informed on emerging trends and market opportunities.Download the full report now to drive data-backed decisions. @ Peripheral T-cell Lymphoma Incidence

Peripheral T-cell Lymphoma Companies and Pipeline Therapies

• Denileukin diftitox: Eisai
• SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
• Fenretinide (4-HPR): CerRx
• Tipifarnib: Kura Oncology
• HBI-8000: HUYA Bioscience International/Quintiles, Inc.
• COPIKTRA (Duvelisib): Verastem
• Genolimzumab (GB226): Genor Biopharma
• Azacitidine (CC-486): Celgene Corporation
• Tislelizumab: BeiGene
• Lacutamab/IPH4102: Innate Pharma
• AFM13: Affimed GmbH
• Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
• Bavencio (avelumab): Pfizer
• Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
• STI-3031/IMC-001: Sorrento Therapeutics
• ALRN 6924: Aileron Therapeutics
• Masitinib: AB Science
• Ruxolitinib: Incyte Corporation/Novartis
• Aplidin (plitidepsin): PharmaMar
• ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals

Discover which Peripheral T-cell Lymphoma therapies are gaining traction, understand patient adoption patterns, and explore the competitive pipeline from leading companies like Eisai, Celgene, Pfizer, and Merck. Download the full report now to stay ahead in strategic planning and identify high-impact opportunities in the evolving PTCL marke @ Peripheral T-cell Lymphoma Drugs and Therapies

Peripheral T-cell Lymphoma Therapeutics Assessment

Top pharmaceutical companies are deeply involved in advancing the Peripheral T-cell Lymphoma (PTCL) therapeutics landscape, concentrating on the development of novel and transformative treatment options expected to shape the future of PTCL care. Key players in this space include Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and several others.

Explore how top pharmaceutical leaders like Eisai, Celgene, and Merck are shaping the future of Peripheral T-cell Lymphoma treatments. Access our detailed report now to uncover breakthrough therapies and strategic market insights driving growth and opportunity.@ Peripheral T-cell Lymphoma Clinical trials and Medication

Peripheral T-cell Lymphoma Report Key Insights

1. Peripheral T-cell Lymphoma Patient Population

2. Peripheral T-cell Lymphoma Market Size and Trends

3. Key Cross Competition in the Peripheral T-cell Lymphoma Market

4. Peripheral T-cell Lymphoma Market Dynamics (Key Drivers and Barriers)

5. Peripheral T-cell Lymphoma Market Opportunities

6. Peripheral T-cell Lymphoma Therapeutic Approaches

7. Peripheral T-cell Lymphoma Pipeline Analysis

8. Peripheral T-cell Lymphoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Peripheral T-cell Lymphoma Market

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services